Marlborough biotech Advanced Cell Technology Inc. has chosen Oregon Health & Science University as a site for a macular degeneration therapy clinical trial.
The treatment uses cells derived from human embryonic stem cells. The trial is intended to determine the safety and tolerability of the cells, following their transplantation into patients with Stargardt’s macular dystrophy.
Jules Stein Institute at the University of California, Los Angeles has also been approved as a site for the trial.
